U.S. public health agency validated digital PCR technologies – including QIAcuity – as the way to reliably detect multiple disease targets in wastewater samples
QIAcuity previously awarded U.S. contract for public health labs utilization in 70% of all U.S. states
QIAGEN offers broad portfolio to address demands for testing beyond pandemic
HILDEN, Germany & GERMANTOWN, Md., June 01, 2022--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomed an endorsement from the National Wastewater Surveillance System (NWSS) of the U.S. Centers for Disease Control and Prevention (CDC) and their validation and approval for the use of two digital PCR systems – including the QIAcuity digital PCR system – for wastewater surveillance of 30 pathogens, including the SARS-CoV-2 virus.
The decision of the U.S. national public health agency marks a step away from the traditional quantitative PCR (qPCR) approach to the novel digital PCR technology as a more reliable detection method. Digital PCR (dPCR) can quantify the tiniest traces of DNA and RNA – and recently also the proteins encoded by these genetic materials – to test for infectious diseases caused by viruses and bacteria, and other disorders like cancer mutations. The CDC will now develop the wastewater pathogen assays and provide them to public health labs to run on either system, thereby converting their current qPCR assays to dPCR testing.
The decision by the NWSS also means that the CDC will only accept wastewater surveillance data collected with QIAcuity or the other approved digital PCR instrument, and that related public funding through the CDC’s Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) Cooperative Agreement will be limited to the use of one of these two platforms. The ELC supports state, local, and regional health departments in the detection, prevention, and response to emerging infectious diseases.
The approval comes after QIAGEN previously completed a U.S. government contract to equip public health laboratories across the country with QIAcuity dPCR devices, initially to monitor the spread of COVID-19 by testing wastewater. More than 70% of U.S. states now have at least one public or privately-owned laboratory that can monitor wastewater with QIAcuity, a system that has set new standards by delivering results in two hours.
Wastewater surveillance has a broad range of applications beyond COVID-19 testing and can be used to protect communities from a variety of infectious diseases, such as the detection of antimicrobial resistant "superbugs" and food-borne diseases such as E. coli or Listeria.
"The CDC’s decision is a testament to the quality and robustness of our QIAcuity dPCR system and is further proof of the reputation it is gaining among public health experts in- and outside the United States," said Thomas Schweins, Ph.D., Senior Vice President, Life Science Business Area at QIAGEN. "The CDC protocol covers a multitude of targets beyond COVID-19, which shows that our portfolio – including QIAcuity as one of our five growth pillars – has a huge relevance for many other infectious diseases."
QIAGEN is currently expanding the QIAcuity menu into new research applications, such as proteomics, and also expansion into clinical healthcare. The analysis of the interactions between different proteins and between proteins and genetic material is meant to complement genomic analysis and give more comprehensive pictures of diseases.
Digital PCR is more accurate and sensitive than traditional qPCR as it more precisely quantifies nucleic acids and target sequences of DNA and RNA. The technology’s success in wastewater testing shows its potential in disease surveillance more generally. Surveillance allows public authorities to collect data from broad sweeps of the population and give early warnings about outbreaks of infectious diseases.
More information about QIAGEN solutions for wastewater testing can be found here.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2022, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Source: QIAGEN N.V. Category: Corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601006158/en/
QIAGEN: Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com Public Relations Thomas Theuringer +49 2103 29 11826 e-mail: pr@QIAGEN.com
Moderna says its Omicron-specific bivalent COVID-19 vaccine is likely candidate for fall boosters.
Early results from a late-stage study in a rare blood disorder showed that patients given a placebo at some clinical trial sites in Eastern Europe performed better than those on drug.
Shares of Veru (NASDAQ: VERU) surged 16.8% on Tuesday, after the biopharmaceutical company submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its novel coronavirus oral drug candidate, sabizabulin. Sabizabulin is a once-daily antiviral and anti-inflammatory treatment for hospitalized patients with moderate to severe COVID-19, who are at high risk of acute respiratory distress syndrome. "COVID-19 new cases and hospitalizations are on the rise again with a summer and fall-winter peaks expected," Veru CEO Mitchell Steiner said in a press release.
Recent IBD Stock Of The Day Vertex Pharmaceuticals briefly broke out Wednesday on promising test results in diabetes.
Nurses' clinical expertise and patient experience provide valuable insight across all divisions of our company
Vitamin D helps your body build strong bones, lower the risk of osteoporosis, and more. Here's what you can do to make sure you get enough vitamin D every day.
Yahoo Finance's Anjalee Khemlani joins the Live show to detail Novavax's FDA approval for its two-dose COVID vaccine for adults.
What happened Shares of Novavax (NASDAQ: NVAX) were jumping 3.1% as of 10:01 a.m. ET on Wednesday after rising as much as 11.3% earlier in the day. The move came after a U.S. Food and Drug Administration (FDA) advisory committee voted 21-0 with one abstention on Tuesday in favor of recommending Emergency Use Authorization (EUA) for Novavax's COVID-19 vaccine NVX-CoV2373.
With COVID-19 cases surging again, many people are wondering what the future of the global pandemic will look like in the United States. Amid the uncertainty, however, a recently authorized antiviral treatment and a new Moderna booster expected to arrive in the fall have experts suggesting there could be an end in sight.
Dramatic levels of weight loss are being attained in clinical trials of drugs originally developed for diabetes.
Risk of heart inflammation from mRNA vaccines is being studied, creator says.
Is Merck stock a buy after the company guided to $5 billion to $5.5 billion in sales of its Covid pill this year? Is MRK stock a buy now?
Delcath Systems Inc (NASDAQ: DCTH) announced further details regarding presentations relating to its proprietary percutaneous hepatic perfusion (PHP) system. The CHOPIN trial assessed ipilimumab plus nivolumab (IPI+NIVO) combined with Delcath's proprietary liver-targeted PHP treatment in metastatic uveal melanoma patients. The poster reports a Best Overall Response of 1 complete response, five partial responses, and one stable disease accounting for an Objective Response Rate of 85.7%. Related:
Gary Kracoff and John Walczyk have been writing their Over the Counter column for the past 12 years. This final column is about a healthy lifestyle.
241 counties are considered at high levels as of Tuesday.
When investors think of growth opportunities, their attention typically gravitates to the high-powered tech arena. Not only is it stable, with prices that increase along with inflation, but a recent study highlighted why there could be yet another growth opportunity there that could unlock even more potential. Dentists generate recurring revenue from patients over the years.
A fourth COVID vaccine could be coming to market soon. On Tuesday, a FDA panel recommended that a vaccine from Maryland-based biotechnology company Novavax be approved for emergency use authorization.
Most of the surrounding counties have been at a high level for weeks, but now Manatee cases are increasing.
“Several factors likely affect crude case rates.”
After backpacking around Morocco, a U.S. traveler was left stunned by a Moroccan hospital bill that he received on the last day.